Supplementary Table 1.
Clinical Characteristics of DCC, DCNC, UC, PDC, PDNC, and HV Groups
| Variable | DCC | DCNC | UC | PD-1 checkpoint inhibitor-related colitis | PD-1 checkpoint inhibitor no colitis | HVs |
|---|---|---|---|---|---|---|
| n | 15 | 10 | 10 | 7 | 5 | 22 |
| Age, y, median (IQR) | 69 (59–70) | 60 (54–70) | 44 (34–49) | 64 (61–71) | 72 (70–74) | 67 (50–73) |
| Sex, male, n (%) | 10 (67) | 3 (30) | 6 (60) | 6 (86) | 4 (80) | 12 (55) |
| Cancer | NA | NA | ||||
| Melanoma stage, n | ||||||
| IIIB | 1 | 1 | 0 | 2 | ||
| IIIC | 1 | 2 | 0 | 0 | ||
| IIID | 0 | 0 | 1 | 1 | ||
| IV | 11 | 7 | 0 | 0 | ||
| Renal | 2 | 0 | 3 | 1 | ||
| Lung | 0 | 0 | 3 | 1 | ||
| Serum LDH,aU/L, median (IQR) | 259 (222–301) | 289 (259–331) | NA | 216 (210–235) | 210 (205–227) | NA |
| Distribution of UC | NA | NA | 4 Pancolitis 6 Left-sided colitis |
NA | NA | NA |
| Time from UC diagnosis to endoscopy, mo, median (IQR) | NA | NA | 50 (41–161) | NA | NA | NA |
| Time from diarrhoea onset to endoscopy, d, median (IQR) | 10 (6–29) | 9 (3–26) | 27 (1–49) | 16 (9–17) | 12 (11–13) | NA |
| Patients on steroids at endoscopy, n (%) | 12 (80) | 5 (50) | 3 (30) | 2 (29) | 0 (0) | NA |
| Time on steroids at endoscopy, d, median (IQR) | 21 (28–63) | 16 (2–27) | 45 (40–54) | 32 (19–45) | 0 (0) | NA |
| Colitis treatment, n | NA | NA | NA | |||
| Mesalazine | 0 | 7 | 0 | |||
| Prednisolone | 15 | 6 | 7 | |||
| Intravenous methylprednisone | 11 | 0 | 0 | |||
| Azathioprine | 0 | 3 | 0 | |||
| Mycophenolate mofetil | 1 | 0 | 0 | |||
| Infliximab | 8b | 3c | 2d | |||
| Adalimumab | 0 | 1 | 0 | |||
| Vedolizumab | 4d | 3e | 0 | |||
| FMT | 1d | 0 | 1d | |||
| Tofacitinib | 0 | 0 | 1d | |||
| Colectomy | 0 | 0 | 0 | |||
| Endoscopic findings (UCEIS score), n | ||||||
| 0 | 0 | 10 | 0 | 1 | 5 | 22 |
| 1 | 4 | 0 | 2 | 0 | 0 | 0 |
| 2 | 1 | 0 | 0 | 2 | 0 | 0 |
| 3 | 3 | 0 | 2 | 0 | 0 | 0 |
| 4 | 4 | 0 | 1 | 3 | 0 | 0 |
| 5 | 1 | 0 | 5 | 1 | 0 | 0 |
| 6 | 2 | 0 | 0 | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Histologic findings, n | NA | |||||
| Focal active colitis | 2 | 0 | 0 | 0 | 0 | |
| Collagenous colitis | 1 | 0 | 0 | 2 | 0 | |
| Lymphocytic colitis | 1 | 0 | 0 | 1 | 0 | |
| IBD-like colitis | 7 | 0 | 10 (UC) | 1 | 0 | |
| Infectious/NSAID-like colitis | 3 | 0 | 0 | 3 | 0 | |
| Normal | 1 | 10 | 0 | 0 | 5 | |
| Nancy score, n | NA | |||||
| 0 | 0 | 10 | 0 | 1 | 5 | |
| 1 | 3 | 0 | 1 | 1 | 0 | |
| 2 | 5 | 0 | 3 | 3 | 0 | |
| 3 | 5 | 0 | 4 | 2 | 0 | |
| 4 | 2 | 0 | 2 | 0 | 0 |
IQR, interquartile range; LDH, lactate dehydrogenase; NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug.
gene Nanostring experiment analyzing RNA extracted from the gastrointestinal tract of HVs (n = 8), patients with active UC (n = 5), anti–CTLA-4/PD-1 colitis (DCC; n = 9) and anti–CTLA-4/PD-1 treated with no colitis (DCNC; n = 8) are shown. Plots show differentially expressed genes in (i) UC vs HV and (ii) DCC vs DCNC and DCC vs UC.
Normal range, 90–235 U/L.
2 of 8 patients were on infliximab at the time of endoscopy and 6 had it subsequently.
2 of 3 patients were on infliximab at the time of endoscopy and 1 had had it prior.
Biologic (or FMT) was given after the endoscopy in patients.
2 of 3 patients were on vedolizumab at the time of endoscopy and 1 had had it prior.